(As of December 12, 2025 | Post Q3 2025 earnings and recent insider transactions)
Current market capitalization: ≈ $398 billion (based on ~$222.70/share and 1.77 billion shares outstanding)
Introduction
AbbVie Inc. (NYSE: ABBV), founded in 2013 as a spinoff from Abbott Laboratories and headquartered in North Chicago, Illinois, is a global biopharmaceutical leader specializing in immunology (e.g., Skyrizi, Rinvoq), oncology, neuroscience (e.g., Vraylar, Botox Therapeutic), and aesthetics (Botox Cosmetic, Juvederm). Public since inception, it uses a single-class share structure (one vote per share) for equitable governance. Ownership is institutionally concentrated (~75%), with insiders ~0.10% (executives and directors), and retail ~25%. The table below details the top 10 economic shareholders from Q3 2025 13F filings and SEC data, with values at current market cap. Recent activity includes $41M+ in insider sales over the past year (e.g., EVP Nicholas Donoghoe sold 58K shares for ~$11.6M in Aug 2025) and $5B quarterly buybacks reducing shares by ~0.5% YoQ.
| Rank | Owner / Stakeholder | Ownership % | Approx. Value ($398B valuation) | Detailed Notes |
|---|---|---|---|---|
| 1 | Vanguard Group Inc. | 10.06% | $40.0 billion | Largest holder via index funds (e.g., VTI, VOO); owns ~177.75M shares as of Sep 30, 2025. Passive with ~$9.3T AUM; added ~3.35M shares (+1.9%) in Q3 2025, core S&P 500 weighting (~6%). No direct control; focuses on immunology growth. |
| 2 | BlackRock Inc. | 8.26% | $32.9 billion | Holds ~145.98M shares through iShares ETFs (e.g., IVV); passive/active mix. Increased ~1.07M shares (+1.2%) in Q3 2025; board observer on governance/ESG. Key in healthcare funds; ABBV ~3% of portfolio. |
| 3 | JPMorgan Chase & Co. | 6.40% | $25.5 billion | ~113.07M shares across asset management; index/active blend. Added ~1.87M shares (+5.2%) in Q3; provides banking/debt for ABBV's $30B+ cash reserves and capex. |
| 4 | State Street Corporation | 4.52% | $18.0 billion | Owns ~79.82M shares via SPDRs (e.g., SPY); fully passive. Slight increase (+0.08%) in Q3; votes proxies on exec comp and drug pricing ethics. ~4% of health holdings; supports $20B annual buybacks. |
| 5 | Morgan Stanley | 2.36% | $9.4 billion | ~41.65M shares via wealth/ETFs; active in advisory. Stable QoQ; engages on shareholder proposals re: antitrust/pipeline risks. |
| 6 | Geode Capital Management, LLC | 2.29% | $9.1 billion | Fidelity affiliate with ~40.44M shares in index trackers; passive. Added ~924K shares (+2.4%) in Q3; tracks S&P 500; minimal voting power. |
| 7 | Charles Schwab Investment Management, Inc. | 1.47% | $5.9 billion | ~25.96M shares; passive via ETFs. Increased in Q3; focuses on dividend yield (3.5%). |
| 8 | Capital Research Global Investors | 1.43% | $5.7 billion | ~25.23M shares in growth strategies; active manager. Trimmed ~7% in Q3 on valuation; holds for oncology (11% of revenues). |
| 9 | Bank of America Corporation | 1.42% | $5.6 billion | ~25.15M shares; strategic peer holding. Stable QoQ; synergies in healthcare financing. |
| 10 | Norges Bank (Norway Sovereign Wealth Fund) | 1.31% | $5.2 billion | ~23.1M shares as of Jun 30, 2025; ethical investing focus, voting on sustainability. Added ~1.6M shares (+5.2%) in Q3; no operational control. |
Total Top 10 = ~39.82% | Remaining: Other Institutions (~35%), Other Insiders (~0%, e.g., CEO Robert Michael at ~0.01%), Retail (~25%) | Grand Total = 100%
Conclusion
As of December 2025, AbbVie's ownership is institutionally dominated (~75% total) by passive giants like Vanguard and BlackRock, ensuring stability for its $15.78B Q3 2025 revenue (up 9.1% YoY, ~50% from immunology) and $188M net income (down 88% YoY due to IPR&D charges), with FY2025 guidance raised to $60.9B revenue and $10.61-10.65 adjusted EPS. Insiders (~0.10% combined) reflect routine sales amid expansions (e.g., Skyrizi/Rinvoq up 40% combined), while retail's ~25% stake highlights defensive pharma appeal. With $398B market cap (up 26% YoY) and $20B buybacks authorized, expect ~0.5% annual share reductions, minor institutional rebalancing in Q4 13Fs (due Feb 2026), and growth from neuroscience (19.6% operational increase). This structure supports pipeline innovation via $6.20 annual dividends (2.8% yield), though Humira erosion and R&D costs (~$9B in 2025) pose risks. For filings, visit SEC EDGAR or AbbVie's investor relations.